Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Adagene Inc ADR (ADAG)

Adagene Inc ADR (ADAG)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.4200 +0.0300 (+2.16%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.4200 unch (unch) 15:52 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3900
Day High
1.4500
Open 1.3900
Previous Close 1.3900 1.3900
Volume 37,900 37,900
Avg Vol 19,595 19,595
Stochastic %K 15.52% 15.52%
Weighted Alpha -47.32 -47.32
5-Day Change -0.1100 (-7.19%) -0.1100 (-7.19%)
52-Week Range 1.3250 - 3.5807 1.3250 - 3.5807
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,483
  • Shares Outstanding, K 47,110
  • Annual Sales, $ 100 K
  • Annual Income, $ -33,420 K
  • EBIT $ 0 M
  • EBITDA $ -35 M
  • 60-Month Beta 0.61
  • Price/Sales 676.92
  • Price/Cash Flow N/A
  • Price/Book 1.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3250 +7.17%
on 04/01/25
Period Open: 1.6400
1.9200 -26.04%
on 04/16/25
-0.2200 (-13.41%)
since 03/25/25
3-Month
1.3250 +7.17%
on 04/01/25
Period Open: 1.9300
2.2700 -37.44%
on 02/27/25
-0.5100 (-26.42%)
since 01/24/25
52-Week
1.3250 +7.17%
on 04/01/25
Period Open: 2.3500
3.5807 -60.34%
on 09/16/24
-0.9300 (-39.57%)
since 04/25/24

Most Recent Stories

More News
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 1.4200 (+2.16%)
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

       - First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics -        - Additional data from...

ADAG : 1.4200 (+2.16%)
Adagene to Participate in Investor Conferences in May and June

SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 1.4200 (+2.16%)
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings...

ADAG : 1.4200 (+2.16%)
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and...

ADAG : 1.4200 (+2.16%)
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging...

ADAG : 1.4200 (+2.16%)
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

- Total potential transaction value of $2.5 billion plus royalties -    SAN DIEGO and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc....

ADAG : 1.4200 (+2.16%)
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 1.4200 (+2.16%)
Adagene Announces Board and Management Appointments to Support Pipeline Growth

SAN DIEGO and SUZHOU, China, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 1.4200 (+2.16%)
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision...

ADAG : 1.4200 (+2.16%)

Business Summary

Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene Inc. is based in SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 1.5100
2nd Resistance Point 1.4800
1st Resistance Point 1.4500
Last Price 1.4200
1st Support Level 1.3900
2nd Support Level 1.3600
3rd Support Level 1.3300

See More

52-Week High 3.5807
Fibonacci 61.8% 2.7190
Fibonacci 50% 2.4528
Fibonacci 38.2% 2.1867
Last Price 1.4200
52-Week Low 1.3250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective